411 related articles for article (PubMed ID: 29861327)
1. PiggyBac-Engineered T Cells Expressing CD19-Specific CARs that Lack IgG1 Fc Spacers Have Potent Activity against B-ALL Xenografts.
Bishop DC; Xu N; Tse B; O'Brien TA; Gottlieb DJ; Dolnikov A; Micklethwaite KP
Mol Ther; 2018 Aug; 26(8):1883-1895. PubMed ID: 29861327
[TBL] [Abstract][Full Text] [Related]
2. Low-cost generation of Good Manufacturing Practice-grade CD19-specific chimeric antigen receptor-expressing T cells using piggyBac gene transfer and patient-derived materials.
Ramanayake S; Bilmon I; Bishop D; Dubosq MC; Blyth E; Clancy L; Gottlieb D; Micklethwaite K
Cytotherapy; 2015 Sep; 17(9):1251-67. PubMed ID: 26212611
[TBL] [Abstract][Full Text] [Related]
3. Inclusion of an IgG1-Fc spacer abrogates efficacy of CD19 CAR T cells in a xenograft mouse model.
Almåsbak H; Walseng E; Kristian A; Myhre MR; Suso EM; Munthe LA; Andersen JT; Wang MY; Kvalheim G; Gaudernack G; Kyte JA
Gene Ther; 2015 May; 22(5):391-403. PubMed ID: 25652098
[TBL] [Abstract][Full Text] [Related]
4. Anti-leukemic potency of piggyBac-mediated CD19-specific T cells against refractory Philadelphia chromosome-positive acute lymphoblastic leukemia.
Saito S; Nakazawa Y; Sueki A; Matsuda K; Tanaka M; Yanagisawa R; Maeda Y; Sato Y; Okabe S; Inukai T; Sugita K; Wilson MH; Rooney CM; Koike K
Cytotherapy; 2014 Sep; 16(9):1257-69. PubMed ID: 25108652
[TBL] [Abstract][Full Text] [Related]
5. Function of Novel Anti-CD19 Chimeric Antigen Receptors with Human Variable Regions Is Affected by Hinge and Transmembrane Domains.
Alabanza L; Pegues M; Geldres C; Shi V; Wiltzius JJW; Sievers SA; Yang S; Kochenderfer JN
Mol Ther; 2017 Nov; 25(11):2452-2465. PubMed ID: 28807568
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy of acute leukemia by chimeric antigen receptor-modified lymphocytes using an improved Sleeping Beauty transposon platform.
Magnani CF; Turazzi N; Benedicenti F; Calabria A; Tenderini E; Tettamanti S; Giordano Attianese GM; Cooper LJ; Aiuti A; Montini E; Biondi A; Biagi E
Oncotarget; 2016 Aug; 7(32):51581-51597. PubMed ID: 27323395
[TBL] [Abstract][Full Text] [Related]
7. CD19 CAR-T Cells With Membrane-Bound IL-15 for B-Cell Acute Lymphoblastic Leukemia After Failure of CD19 and CD22 CAR-T Cells: Case Report.
Sun Y; Su Y; Wang Y; Liu N; Li Y; Chen J; Qiao Z; Niu J; Hu J; Zhang B; Ning H; Hu L
Front Immunol; 2021; 12():728962. PubMed ID: 34691036
[TBL] [Abstract][Full Text] [Related]
8. A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines.
Schneider D; Xiong Y; Wu D; Nӧlle V; Schmitz S; Haso W; Kaiser A; Dropulic B; Orentas RJ
J Immunother Cancer; 2017; 5():42. PubMed ID: 28515942
[TBL] [Abstract][Full Text] [Related]
9. Composite CD79A/CD40 co-stimulatory endodomain enhances CD19CAR-T cell proliferation and survival.
Julamanee J; Terakura S; Umemura K; Adachi Y; Miyao K; Okuno S; Takagi E; Sakai T; Koyama D; Goto T; Hanajiri R; Hudecek M; Steinberger P; Leitner J; Nishida T; Murata M; Kiyoi H
Mol Ther; 2021 Sep; 29(9):2677-2690. PubMed ID: 33940156
[TBL] [Abstract][Full Text] [Related]
10. Eradication of B-ALL using chimeric antigen receptor-expressing T cells targeting the TSLPR oncoprotein.
Qin H; Cho M; Haso W; Zhang L; Tasian SK; Oo HZ; Negri GL; Lin Y; Zou J; Mallon BS; Maude S; Teachey DT; Barrett DM; Orentas RJ; Daugaard M; Sorensen PH; Grupp SA; Fry TJ
Blood; 2015 Jul; 126(5):629-39. PubMed ID: 26041741
[TBL] [Abstract][Full Text] [Related]
11. A new approach to CAR T-cell gene engineering and cultivation using piggyBac transposon in the presence of IL-4, IL-7 and IL-21.
Ptáčková P; Musil J; Štach M; Lesný P; Němečková Š; Král V; Fábry M; Otáhal P
Cytotherapy; 2018 Apr; 20(4):507-520. PubMed ID: 29475789
[TBL] [Abstract][Full Text] [Related]
12.
Li C; Sun Y; Wang J; Tang L; Jiang H; Guo T; Liu L; Wu Y; Ai L; Xia L; Wu J; Lin Z; Qian Q; Hu Y; Mei H
Front Immunol; 2021; 12():599493. PubMed ID: 34113336
[TBL] [Abstract][Full Text] [Related]
13. Inducible secretion of IL-21 augments anti-tumor activity of piggyBac-manufactured chimeric antigen receptor T cells.
Štach M; Ptáčková P; Mucha M; Musil J; Klener P; Otáhal P
Cytotherapy; 2020 Dec; 22(12):744-754. PubMed ID: 32950390
[TBL] [Abstract][Full Text] [Related]
14. Treatment with Humanized Selective CD19CAR-T Cells Shows Efficacy in Highly Treated B-ALL Patients Who Have Relapsed after Receiving Murine-Based CD19CAR-T Therapies.
Zhao Y; Liu Z; Wang X; Wu H; Zhang J; Yang J; Zhang F; Liu L; Long J; Lu P; Chen Z
Clin Cancer Res; 2019 Sep; 25(18):5595-5607. PubMed ID: 31300451
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of piggyBac-mediated anti-CD19 CAR-T cells after ex vivo expansion with aAPCs or magnetic beads.
Yang LR; Li L; Meng MY; Wang WJ; Yang SL; Zhao YY; Wang RQ; Gao H; Tang WW; Yang Y; Yang LL; Liao LW; Hou ZL
J Cell Mol Med; 2021 Jan; 25(2):686-700. PubMed ID: 33225580
[TBL] [Abstract][Full Text] [Related]
16. CAR T Cell Generation by
Bishop DC; Caproni L; Gowrishankar K; Legiewicz M; Karbowniczek K; Tite J; Gottlieb DJ; Micklethwaite KP
Mol Ther Methods Clin Dev; 2020 Jun; 17():359-368. PubMed ID: 32071928
[TBL] [Abstract][Full Text] [Related]
17. Preclinical development of CD37CAR T-cell therapy for treatment of B-cell lymphoma.
Köksal H; Dillard P; Josefsson SE; Maggadottir SM; Pollmann S; Fåne A; Blaker YN; Beiske K; Huse K; Kolstad A; Holte H; Kvalheim G; Smeland EB; Myklebust JH; Inderberg EM; Wälchli S
Blood Adv; 2019 Apr; 3(8):1230-1243. PubMed ID: 30979721
[TBL] [Abstract][Full Text] [Related]
18. T cells expressing CD19-specific Engager Molecules for the Immunotherapy of CD19-positive Malignancies.
Velasquez MP; Torres D; Iwahori K; Kakarla S; Arber C; Rodriguez-Cruz T; Szoor A; Bonifant CL; Gerken C; Cooper LJ; Song XT; Gottschalk S
Sci Rep; 2016 Jun; 6():27130. PubMed ID: 27255991
[TBL] [Abstract][Full Text] [Related]
19. Chimeric Antigen Receptor Therapy in Acute Lymphoblastic Leukemia Clinical Practice.
Luskin MR; DeAngelo DJ
Curr Hematol Malig Rep; 2017 Aug; 12(4):370-379. PubMed ID: 28656487
[TBL] [Abstract][Full Text] [Related]
20. In Vivo Fate and Activity of Second- versus Third-Generation CD19-Specific CAR-T Cells in B Cell Non-Hodgkin's Lymphomas.
Ramos CA; Rouce R; Robertson CS; Reyna A; Narala N; Vyas G; Mehta B; Zhang H; Dakhova O; Carrum G; Kamble RT; Gee AP; Mei Z; Wu MF; Liu H; Grilley B; Rooney CM; Heslop HE; Brenner MK; Savoldo B; Dotti G
Mol Ther; 2018 Dec; 26(12):2727-2737. PubMed ID: 30309819
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
